As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Verona Pharma Plc. The largest reported stake is BlackRock Portfolio Management LLC's, at 6%. 7 filings are on record since August 14, 2025 (Schedule 13G, October 17, 2025).
Sell to companies like Verona Pharma Plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Janus Henderson Group Plc · Sole voting: 0 · Shared voting: 1,010,564 · Sole dispositive: 0 · Shared dispositive: 1,010,564 · SCHEDULE 13G/A, 2025-11-14
- · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-11-14
- · Reporting person: Pentwater Capital Management LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G, 2025-11-14
- · Reporting person: BlackRock Portfolio Management LLC · Sole voting: 27,645,416 · Shared voting: 0 · Sole dispositive: 27,645,624 · Shared dispositive: 0 · SCHEDULE 13G, 2025-10-17
- · Holder: Perceptive Advisors LLC · Percent: 6.4% · SCHEDULE 13G/A
Verona Pharma Plc has 7 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of american depositary shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock Portfolio Management LLC | 6% | 27,645,624 | SCHEDULE 13G, 2025-10-17 | 2025-09-30 |
| Janus Henderson Group Plc | 1.2% | 1,010,564 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| RA Capital Management, L.P. | 0.7% | 593,670 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Perceptive Advisors LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Pentwater Capital Management LP | 0% | 0 | SCHEDULE 13G, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Verona Pharma Plc and the warning signs.
Free to see. No signup.
Keep reading
More on Verona Pharma Plc and the records around it.
Companies that share a holder
- Pentwater Capital Management LP also filed stake reports on 20 other companies: AMC Entertainment Holdings, Inc. (Aug 2026), Caesars Entertainment, Inc. (Aug 2026), Centessa Pharmaceuticals plc (Aug 2026)
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Watch Verona Pharma Plc
Get an email when Verona Pharma Plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Verona Pharma Plc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Verona Pharma Plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Verona Pharma Plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock Portfolio Management LLC | 27,645,416 | 0 | 27,645,624 | 0 | SCHEDULE 13G, 2025-10-17 |
| Janus Henderson Group Plc | 0 | 1,010,564 | 0 | 1,010,564 | SCHEDULE 13G/A, 2025-11-14 |
| Perceptive Advisors LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
| Joseph Edelman | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
| Perceptive Life Sciences Master Fund, Ltd. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
| Pentwater Capital Management LP | 0 | 0 | 0 | 0 | SCHEDULE 13G, 2025-11-14 |
| Matthew Halbower | 0 | 0 | 0 | 0 | SCHEDULE 13G, 2025-11-14 |
The latest filing names Verona Pharma Plc, with its principal executive office as 3 MORE LONDON RIVERSIDE, LONDON (SCHEDULE 13G/A, 2025-11-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Perceptive Advisors LLC | 6.4% | SCHEDULE 13G/A |
| 2025-08-14 | Janus Henderson Group Plc | 7.2% | SCHEDULE 13G/A |
| 2025-08-14 | RA Capital Management, L.P. | 0.7% | SCHEDULE 13G/A |
| 2025-10-17 | BlackRock Portfolio Management LLC | 6% | SCHEDULE 13G |
| 2025-11-14 | Pentwater Capital Management LP | 0% | SCHEDULE 13G |
| 2025-11-14 | Perceptive Advisors LLC | 0% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 1.2% | SCHEDULE 13G/A |
Questions about who owns Verona Pharma Plc
Who owns Verona Pharma Plc?
On this page, one holder's latest ownership filing reports 5% or more of Verona Pharma Plc: BlackRock Portfolio Management LLC (6%, Schedule 13G, filed 2025-10-17).
When did BlackRock Portfolio Management LLC buy into Verona Pharma Plc?
The filings give report dates, not purchase dates. The earliest filing from BlackRock Portfolio Management LLC on this page is the Schedule 13G, filed 2025-10-17, reporting 6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Verona Pharma Plc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.